A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis-Reference-Cited by-同舟云学术

A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

Published:2022-11-15 Issue:Supplement 1 Volume:140 Page:9470-9472
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Patel Krish¹,Riedell Peter A.²,Tilly Hervé³,Ahmed Sairah⁴,Michot Jean-Marie⁵,Ghesquieres Herve⁶,Schiano de Collela Jean Marc⁷,Chanan-Khan Asher⁸,Bouabdallah Kamal⁹,Tessoulin Benoit¹⁰,Iyengar Sunil¹¹,Long Meixiao¹²,Clynes Raphael¹³,Kanodia Jitendra¹³,Bao Lei¹⁴,Ding Ying¹⁵,Jin Jianhua¹³,Ainsworth William B¹⁶,Garcha Raman¹⁶,Kye Steve¹³,Phillips Tycel J.¹⁷

Affiliation:

1. 1Swedish Cancer Institute, Center for Blood Disorders and Cellular Therapy, Seattle, WA

2. 2Department of Medicine, Washington University School of Medicine, Chicago, IL

3. 3Centre Henri Becquerel, Rouen, France

4. 4Department of Lymphoma/Myeloma and Stem Cell Transplantation, MD Anderson Cancer Center, Houston, TX

5. 5Gustave Roussy Cancer Campus, Villejuif, France

6. 6Department of Hematology, Lyon Sud University Hospital/Hospices Civils de Lyon, Pierre Benite, France

7. 7Institut Paoli Calmettes, Department of Hematology, Marseille, France

8. 8Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL

9. 9Hematology Clinic, University Hospital of Bordeaux, Pessac, France

10. 10Hematology Department, Nantes University Hospital, Nantes, France

11. 11Royal Marsden Hospital, London, United Kingdom

12. 12Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH

13. 13Xencor, Inc., Monrovia, CA

14. 14Xencor, San Diego, CA

15. 15Xencor Inc., San Diego, CA

16. 16Xencor, Inc., San Diego, CA

17. 17University of Michigan Medical School, Ann Arbor, MI

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data;International Journal of Molecular Sciences;2024-09-09

2. Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma;Blood;2024-07-18

3. Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma;Expert Review of Anticancer Therapy;2024-06-03

4. Bispecific and multispecific antibodies in oncology: opportunities and challenges;Nature Reviews Clinical Oncology;2024-05-31

5. T-Cell Engagers—The Structure and Functional Principle and Application in Hematological Malignancies;Cancers;2024-04-20